« Big Pharma And Its Research Publications |
| Mannkind's Latest Data »
August 15, 2013
Aileron Reports Some Stapled Peptide Results
Here's a publication from Aileron Therapeutics on their stapled-peptide efforts against MDM2/p53 for cancer. (I wrote about that target here, so you can check out the links in that post for background). This compound (ATSP-7041) goes after both MDM2 and MDMX, activating the suppressed p53 pathway, and it seems to do a good job of it. The company's been talking about these results at conferences, but this is the official publication of all that data.
Stapled peptides as a class of potential drugs have been the subject of controversy, but this one is heading towards the clinic, by all accounts. There are several other compounds out there in the same MDM2 space, though, so it'll be interesting to see how they all fare in the real world. And it's also worth noting that a good number of the people on this PNAS paper may well have been let go by Aileron in the last few months. . .
+ TrackBacks (0) | Category: Cancer
POST A COMMENT
- RELATED ENTRIES
- XKCD on Protein Folding
- The 2014 Chemistry Nobel: Beating the Diffraction Limit
- German Pharma, Or What's Left of It
- Sunesis Fails with Vosaroxin
- A New Way to Estimate a Compound's Chances?
- Meinwald Honored
- Molecular Biology Turns Into Chemistry
- Speaking at Northeastern